Literature DB >> 16847754

Degradation and beyond: control of androgen receptor activity by the proteasome system.

Tomasz Jaworski1.   

Abstract

The androgen receptor (AR) is a transcription factor belonging to the family of nuclear receptors which mediates the action of androgens in the development of urogenital structures. AR expression is regulated post-translationally by the ubiquitin/proteasome system. This regulation involves more complex mechanisms than typical degradation. The ubiquitin/proteasome system may regulate AR via mechanisms that do not engage in receptor turnover. Given the critical role of AR in sexual development, this complex regulation is especially important. Deregulation of AR signalling may be a causal factor in prostate cancer development. AR is the main target in prostate cancer therapies. Due to the critical role of the ubiquitin/proteasome system in AR regulation, current research suggests that targeting AR degradation is a promising approach.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16847754      PMCID: PMC6275697          DOI: 10.2478/s11658-006-0011-9

Source DB:  PubMed          Journal:  Cell Mol Biol Lett        ISSN: 1425-8153            Impact factor:   5.787


  104 in total

1.  N-Terminally extended human ubiquitin-conjugating enzymes (E2s) mediate the ubiquitination of RING-finger proteins, ARA54 and RNF8.

Authors:  K Ito; S Adachi; R Iwakami; H Yasuda; Y Muto; N Seki; Y Okano
Journal:  Eur J Biochem       Date:  2001-05

Review 2.  The proteasome: a proteolytic nanomachine of cell regulation and waste disposal.

Authors:  Dieter H Wolf; Wolfgang Hilt
Journal:  Biochim Biophys Acta       Date:  2004-11-29

Review 3.  Androgen receptor signaling in androgen-refractory prostate cancer.

Authors:  M E Grossmann; H Huang; D J Tindall
Journal:  J Natl Cancer Inst       Date:  2001-11-21       Impact factor: 13.506

4.  Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor.

Authors:  H K Lin; S Yeh; H Y Kang; C Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-12       Impact factor: 11.205

5.  Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex.

Authors:  Zhigang Kang; Asta Pirskanen; Olli A Jänne; Jorma J Palvimo
Journal:  J Biol Chem       Date:  2002-10-09       Impact factor: 5.157

6.  Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells.

Authors:  Hui-Kuan Lin; Yueh-Chiang Hu; Dong Kun Lee; Chawnshang Chang
Journal:  Mol Endocrinol       Date:  2004-06-17

7.  C-terminal Hsp-interacting protein slows androgen receptor synthesis and reduces its rate of degradation.

Authors:  Christopher P Cardozo; Charlene Michaud; Michael C Ost; Albert E Fliss; Emy Yang; Cam Patterson; Simon J Hall; Avrom J Caplan
Journal:  Arch Biochem Biophys       Date:  2003-02-01       Impact factor: 4.013

8.  Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone.

Authors:  Z Culig; A Hobisch; M V Cronauer; A C Cato; A Hittmair; C Radmayr; J Eberle; G Bartsch; H Klocker
Journal:  Mol Endocrinol       Date:  1993-12

9.  Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity.

Authors:  Thomas R Salas; Jeri Kim; Funda Vakar-Lopez; Anita L Sabichi; Patricia Troncoso; Guido Jenster; Akira Kikuchi; Shao-Yong Chen; Lirim Shemshedini; Milind Suraokar; Christopher J Logothetis; John DiGiovanni; Scott M Lippman; David G Menter
Journal:  J Biol Chem       Date:  2004-02-24       Impact factor: 5.157

10.  The RING finger protein SNURF modulates nuclear trafficking of the androgen receptor.

Authors:  H Poukka; U Karvonen; N Yoshikawa; H Tanaka; J J Palvimo; O A Jänne
Journal:  J Cell Sci       Date:  2000-09       Impact factor: 5.285

View more
  15 in total

1.  A novel prostate cancer therapeutic strategy using icaritin-activated arylhydrocarbon-receptor to co-target androgen receptor and its splice variants.

Authors:  Feng Sun; Inthrani R Indran; Zhi Wei Zhang; M H Eileen Tan; Yu Li; Z L Ryan Lim; Rui Hua; Chong Yang; Fen-Fen Soon; Jun Li; H Eric Xu; Edwin Cheung; Eu-Leong Yong
Journal:  Carcinogenesis       Date:  2015-04-23       Impact factor: 4.944

Review 2.  Targeting the turnover of oncoproteins as a new avenue for therapeutics development in castration-resistant prostate cancer.

Authors:  Shan Wang; Dede N Ekoue; Ganesh V Raj; Ralf Kittler
Journal:  Cancer Lett       Date:  2018-09-11       Impact factor: 8.679

3.  A 629RKLKK633 motif in the hinge region controls the androgen receptor at multiple levels.

Authors:  Tamzin M Tanner; Sarah Denayer; Bart Geverts; Nora Van Tilborgh; Stefanie Kerkhofs; Christine Helsen; Lien Spans; Vanessa Dubois; Adriaan B Houtsmuller; Frank Claessens; Annemie Haelens
Journal:  Cell Mol Life Sci       Date:  2010-02-26       Impact factor: 9.261

Review 4.  The 26S proteasome complex: an attractive target for cancer therapy.

Authors:  Sarah Frankland-Searby; Sukesh R Bhaumik
Journal:  Biochim Biophys Acta       Date:  2011-10-18

5.  Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer.

Authors:  David T Hoang; Lei Gu; Zhiyong Liao; Feng Shen; Pooja G Talati; Mateusz Koptyra; Shyh-Han Tan; Elyse Ellsworth; Shilpa Gupta; Heather Montie; Ayush Dagvadorj; Saija Savolainen; Benjamin Leiby; Tuomas Mirtti; Diane E Merry; Marja T Nevalainen
Journal:  Mol Cancer Ther       Date:  2014-12-31       Impact factor: 6.261

6.  Androgen receptor W741C and T877A mutations in AIDL cells, an androgen-independent subline of prostate cancer LNCaP cells.

Authors:  Takashi Otsuka; Kazuhiro Iguchi; Kazuhiro Fukami; Kenichiro Ishii; Shigeyuki Usui; Yoshiki Sugimura; Kazuyuki Hirano
Journal:  Tumour Biol       Date:  2011-07-20

7.  Nuclear export signal of androgen receptor (NESAR) regulation of androgen receptor level in human prostate cell lines via ubiquitination and proteasome-dependent degradation.

Authors:  Yanqing Gong; Dan Wang; Javid A Dar; Prabhpreet Singh; Lara Graham; Weijun Liu; Junkui Ai; Zhongcheng Xin; Yinglu Guo; Zhou Wang
Journal:  Endocrinology       Date:  2012-10-05       Impact factor: 4.736

8.  Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.

Authors:  Tadas Vasaitis; Aashvini Belosay; Adam Schayowitz; Aakanksha Khandelwal; Pankaj Chopra; Lalji K Gediya; Zhiyong Guo; Hong-Bin Fang; Vincent C O Njar; Angela M H Brodie
Journal:  Mol Cancer Ther       Date:  2008-08       Impact factor: 6.261

9.  Elevated LIM kinase 1 in nonmetastatic prostate cancer reflects its role in facilitating androgen receptor nuclear translocation.

Authors:  Katerina Mardilovich; Mads Gabrielsen; Lynn McGarry; Clare Orange; Rachana Patel; Emma Shanks; Joanne Edwards; Michael F Olson
Journal:  Mol Cancer Ther       Date:  2014-10-24       Impact factor: 6.261

10.  USP10 deubiquitylates the histone variant H2A.Z and both are required for androgen receptor-mediated gene activation.

Authors:  Ryan Draker; Elizabeth Sarcinella; Peter Cheung
Journal:  Nucleic Acids Res       Date:  2011-01-17       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.